Search research articles
Contact Us
Filters
Showing results (121-130 of 346) with videos related to
Page
of 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
Christian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
European Urology
|
September 20, 2011
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01)
Stéphane Culine, Aude Fléchon, Aline Guillot, et al.
Sleep
|
October 8, 2021
Rest activity rhythms characteristics of breast cancer women following endocrine therapy
Tristan Martin, Mylène Duivon, Nicolas Bessot, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 6, 2007
CD8 T cell help for innate antitumor immunity
Anil Shanker, Grégory Verdeil, Michel Buferne, et al.
American Journal of Clinical Oncology
|
June 7, 2006
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer
Hugues Bourgeois, Aurélie Ferru, Alain Lortholary, et al.
Springerplus
|
February 3, 2016
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
Katharina Gunzer, Florence Joly, Jean-Marc Ferrero, et al.
Bulletin Du Cancer
|
December 21, 2019
[Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer]
Quiterie de Fréminville, Idlir Licaj, Jean-Sebastien Frenel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 12, 2017
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, et al.
Journal of Geriatric Oncology
|
August 29, 2018
Prospective comparison of the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) in geriatric oncology
Audrey Rambeau, Bérengère Beauplet, Heidi Laviec, et al.
Frontiers in Oncology
|
November 3, 2022
How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study
Angélique Da Silva, Aude Fléchon, Elodie Coquan, et al.
Page
of 35
Search research articles
Search
Showing results (121-130 of 346) with videos related to
Sort By:
Page
of 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
Christian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
European Urology
|
September 20, 2011
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01)
Stéphane Culine, Aude Fléchon, Aline Guillot, et al.
Sleep
|
October 8, 2021
Rest activity rhythms characteristics of breast cancer women following endocrine therapy
Tristan Martin, Mylène Duivon, Nicolas Bessot, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 6, 2007
CD8 T cell help for innate antitumor immunity
Anil Shanker, Grégory Verdeil, Michel Buferne, et al.
American Journal of Clinical Oncology
|
June 7, 2006
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer
Hugues Bourgeois, Aurélie Ferru, Alain Lortholary, et al.
Springerplus
|
February 3, 2016
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
Katharina Gunzer, Florence Joly, Jean-Marc Ferrero, et al.
Bulletin Du Cancer
|
December 21, 2019
[Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer]
Quiterie de Fréminville, Idlir Licaj, Jean-Sebastien Frenel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 12, 2017
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, et al.
Journal of Geriatric Oncology
|
August 29, 2018
Prospective comparison of the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) in geriatric oncology
Audrey Rambeau, Bérengère Beauplet, Heidi Laviec, et al.
Frontiers in Oncology
|
November 3, 2022
How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study
Angélique Da Silva, Aude Fléchon, Elodie Coquan, et al.
Page
of 35